← All trials
NCT03547271
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2018
- Primary completion
- Jul 8, 2021
- Completion date
- Jul 8, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 1540
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sanofi-AventisLead sponsor
- Sanofi-AventisStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- pneumococcal 13-valent conjugate vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- measles, mumps, and rubella vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.